NIKKEI 225
39,341.54 -325.53 (-0.82%) HANG SENG
17,716.47 -373.46 (-2.06%) CRUDE OIL
81.81 +0.91 (+1.12%) GOLD FUTURES
2,338.70 +25.50 (+1.10%) DOW
39,164.06 +36.26 (+0.09%) Bitcoin GBP
48,607.91 +401.15 (+0.83%)
ANGO Jan 2025 10.000 call
| Previous close | 0.4500 |
| Open | 0.2400 |
| Bid | 0.0000 |
| Ask | 0.5500 |
| Strike | 10.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.2400 - 0.4500 |
| Contract range | N/A |
| Volume | |
| Open interest | 15 |
ZacksAngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval
AngioDynamics (ANGO) announces the European CE Mark approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
Simply Wall St.Investors in AngioDynamics (NASDAQ:ANGO) have unfortunately lost 75% over the last three years
Every investor on earth makes bad calls sometimes. But really big losses can really drag down an overall portfolio. So...
Business WireAngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System
LATHAM, N.Y., May 21, 2024--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced European CE Mark approval of the AlphaVac F1885 System for the non-surgical removal of thrombi or emboli from the pulmonary arteries and for the treatment of pulmonary embolism (PE).
